Cargando…

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Detalles Bibliográficos
Autores principales:	Bjorklund, Chad C., Kang, Jian, Amatangelo, Michael, Polonskaia, Ann, Katz, Mark, Chiu, Hsiling, Couto, Suzana, Wang, Maria, Ren, Yan, Ortiz, Maria, Towfic, Fadi, Flynt, J. Erin, Pierceall, William, Thakurta, Anjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214241/ https://www.ncbi.nlm.nih.gov/pubmed/31719682 http://dx.doi.org/10.1038/s41375-019-0620-8

Ejemplares similares

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014)

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
por: Amatangelo, M., et al.
Publicado: (2022)

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
por: Shimizu, Nobuyuki, et al.
Publicado: (2021)

High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
por: Heim, Christopher, et al.
Publicado: (2022)

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
por: Li, Lifeng, et al.
Publicado: (2020)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
por: Heim, Christopher, et al.
Publicado: (2019)

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
por: Jones, J. R., et al.
Publicado: (2021)

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: van de Donk, N. W. C. J, et al.
Publicado: (2022)

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
por: Hagner, Patrick R., et al.
Publicado: (2022)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
por: Tateno, Shumpei, et al.
Publicado: (2020)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples
por: Ren, Yan, et al.
Publicado: (2016)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Cereblon/CRBN在弥漫大B细胞淋巴瘤中的表达及其与预后的关系
Publicado: (2020)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
por: Ortiz-Estévez, María, et al.
Publicado: (2021)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4(CRBN) Protein Degradation Axis
por: Yang, Seung-Joo, et al.
Publicado: (2021)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

PB1958: IN SILICO ANALYSIS OF SYNONYMOUS AND NON-SYNONYMOUS SNPS OF THE HUMAN CEREBLON (CRBN) GENE: AN IMPORTANT GENE IN IMMUNOMODULATORY DRUGS (IMIDS)-BASED TREATMENT OF MULTIPLE MYELOMA PATIENTS
por: Güler, M., et al.
Publicado: (2022)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
por: Hao, Bing-bing, et al.
Publicado: (2020)

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
por: Lopez-Millan, Belen, et al.
Publicado: (2017)

Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide
por: Davis, David A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qagdltdv7v57ntguvkhl45tquv